Testosterone Therapy Slightly Increases Prostate Growth But Doesn't Worsen Urinary Symptoms

This comprehensive study addresses a key concern for men considering testosterone replacement therapy: whether it significantly affects prostate health and urinary function. The research matters because up to 20% of aging men have low testosterone, while 80% develop prostate enlargement, making the interaction between hormone therapy and prostate health crucial for healthy aging.

Researchers followed 511 men from 2004 to 2017, conducting annual evaluations including prostate ultrasounds, urine tests, PSA measurements, and symptom questionnaires. Of these men, 167 were diagnosed with symptomatic low testosterone and received replacement therapy, allowing researchers to compare the same individuals during treated and untreated periods.

The key finding was that testosterone therapy increased prostate growth rate by 0.22 mL per year compared to untreated periods—a statistically significant but clinically modest increase. Importantly, this enlargement didn't worsen urinary symptoms, quality of life scores, or PSA levels, suggesting the prostate changes may be less functionally significant than previously feared.

For longevity-focused individuals, this research provides reassuring evidence that testosterone therapy's prostate effects may be manageable. The study suggests men with low testosterone shouldn't automatically avoid hormone replacement due to prostate concerns, though monitoring remains important. However, the research was retrospective and observational, limiting definitive conclusions about causation. The findings support a nuanced approach to testosterone therapy, weighing benefits against modest prostate changes while maintaining appropriate medical surveillance.